BlackRock Health Sciences Trust II (0PR)
XFRA 
Summary
0PR Chart
BMEZ Tender Offer Quick Notes
BlackRock Health Sciences Term Trust will conduct a tender offer for up to 5% of its shares at 98% of NAV, expected to run from October 16 to November 18, 2026. The tender triggered automatically because BMEZ's average discount over the nine months ended September 30 was -11.05%, wider than the program's -10% threshold. At a -10.42% discount (October 12 close), tendering captures about 9.4% of alpha per accepted share, but only about 10% of tendered shares would be accepted at 50% participation.
BMEZ: Ride On Multiple Tailwinds Amid Sector Rotation
BlackRock Health Sciences Trust II offers a balanced biotech and pharma portfolio, with top holdings showing strong FCF margins and positive growth. BMEZ trades at a notable -10% NAV discount, presenting an attractive entry point as sector rotation into healthcare gains momentum. I expect healthcare to outperform through 2026, driven by lower valuations, technological innovation, and defensive positioning during midterm election cycles.
BMEZ: Removal Of Options Should Improve Performance (Rating Upgrade)
BlackRock Health Sciences Trust II offers exposure to healthcare innovation but faces NAV instability and dividend sustainability concerns. BMEZ's strategy targets high-growth healthcare sectors, leveraging BlackRock's expertise, yet recent performance highlights volatility and risk to distributions. Potential growth in healthcare is supported by industry trends, but BMEZ's NAV fluctuations and payout risks warrant close monitoring.
BlackRock Health Sciences Trust II (0PR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BlackRock Health Sciences Trust II ever had a stock split?
BlackRock Health Sciences Trust II Profile
| XFRA Exchange | US Country |
Overview
BlackRock Health Sciences Term Trust is a distinct entity operating as a closed-end management investment company. Established on August 14, 2019, and based in Wilmington, DE, the Trust's primary mission is to deliver a comprehensive return to its investors. This is achieved through a blend of current income, current gains, and the potential for long-term capital appreciation. The Trust strategically focuses on the health sciences sector, aiming to leverage the growing demand and advancements within this field to generate returns for its investors.
Products and Services
BlackRock Health Sciences Term Trust offers a specialized suite of investment products focused on the health sciences sector, aiming to cater to a wide range of investor needs through:
- Total Return and Income Strategy: This product targets a mix of current income and long-term capital appreciation. It is designed for investors looking for a balanced approach to earning from their investments in health sciences, incorporating both regular income and the possibility of gains from increasing asset values over time.
- Current Gains Strategy: Focused more on the short to medium term, this strategy aims to provide gains from current investments. It is ideal for investors seeking quicker returns from their investments in the health sciences sector, perhaps to capitalize on market movements or specific sector advancements.
- Long-Term Capital Appreciation Strategy: For investors with a longer time horizon, this approach emphasizes the growth potential of investments within the health sciences. It aims to benefit from the sector's long-term advancements and innovations, offering the prospect of significant returns over time.
Contact Information
